A clinical prediction rule to estimate the probability of mediastinal metastasis in patients with non-small cell lung cancer.
BACKGROUND
Estimating the clinical probability of mediastinal metastasis in patients with non-small cell lung cancer (NSCLC) can facilitate the selection and interpretation of staging tests.


OBJECTIVE
We sought to identify independent clinical predictors of mediastinal metastasis and to develop a prediction rule to estimate the pretest probability of nodal metastasis in patients with NSCLC.


METHODS
We used data from a randomized controlled trial of selective versus routine mediastinoscopy to develop a clinical prediction model.


RESULTS
Five hundred sixty-six patients were included, with a mean age of 65 +/- 9 years; 31% had positive lymph nodes. Independent predictors of positive nodes included adenocarcinoma or large cell histology (OR 2.6, 95% confidence interval [CI] = 1.8-3.9), apparent metastatic disease on chest radiography (OR 2.4, 95% CI = 1.2-4.7), central location of the primary tumor (OR 2.1, 95% CI = 1.4-3.3), symptoms from the primary tumor (OR 1.6, 95% CI = 1.1-2.4), tumor diameter > or =3.6 cm (OR 1.5, 95% CI = 1.0-2.3), and age less than 65 years (OR 1.5, 95% CI = 1.0-2.2). Model accuracy and calibration were good, with an area under the receiver operating characteristic curve of 0.70 (95% CI = 0.66-0.75) and good agreement between observed and predicted probabilities of mediastinal metastasis.


CONCLUSIONS
Our prediction rule can be used to estimate the pretest probability of mediastinal metastasis in patients with NSCLC. Such estimates can facilitate clinical decision making when selecting and interpreting the results of noninvasive and invasive staging tests.
Shafazand
Shirin
S
Division of Pulmonary and Critical Care Medicine, University of Miami, Miller School of Medicine, Miami, Florida 33101, USA. sshafazand@med.miami.edu
Gould
Michael K
MK
D000367:Age Factors; D000368:Aged; D001707:Biopsy, Needle; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D016001:Confidence Intervals; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D008198:Lymph Nodes / Q000473:pathology*; D008297:Male; D008479:Mediastinal Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy; D008481:Mediastinoscopy; D008875:Middle Aged; D009367:Neoplasm Staging; D016017:Odds Ratio; D011237:Predictive Value of Tests; D011336:Probability; D011379:Prognosis; D018570:Risk Assessment; D012737:Sex Factors; D016019:Survival Analysis; D016896:Treatment Outcome